The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.

[1]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[2]  F. Wolfe,et al.  Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.

[3]  K. Sliwa,et al.  Therapy of Ischemic Cardiomyopathy With the Immunomodulating Agent Pentoxifylline: Results of a Randomized Study , 2004, Circulation.

[4]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[5]  T. Inomata,et al.  Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[6]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[7]  N. Papadopoulos,et al.  Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. , 2002, The Journal of rheumatology.

[8]  S. Fichtlscherer,et al.  Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure , 2001, Circulation.

[9]  R. Straub,et al.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[10]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[11]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[12]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[13]  K. Stengaard-Pedersen,et al.  The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells. , 2000, Clinical and experimental rheumatology.

[14]  R. Holubkov,et al.  Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  G. Christensen,et al.  Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. , 2000, Cardiovascular research.

[16]  W. Colucci,et al.  Interleukin-1β and Tumor Necrosis Factor-α Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro , 2000 .

[17]  K. Webster,et al.  Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. , 1999, Circulation research.

[18]  B. Gandek,et al.  Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey. , 1998, Journal of clinical epidemiology.

[19]  B. Cronstein,et al.  Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. , 1998, The Journal of clinical investigation.

[20]  D. Furst.  The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. , 1997, British journal of rheumatology.

[21]  M. Entman,et al.  Tumor Necrosis Factor-α Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes , 1997 .

[22]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[23]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[24]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[25]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[26]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.